SCHEMBL2906821

SCHEMBL2906821

OCCNCc1cn(-c2ccc(-c3ccc(F)cc3)cc2)nc1-c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
MAPT P10636 5/20 0.54
KDM4E B2RXH2 4/20 0.54
NPC1 O15118 1/20 0.54
LMNA P02545 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MAPK1 P28482 2/20 0.50
HTT P42858 2/20 0.50
XBP1 P17861 1/20 0.50
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
GAA P10253 2/20 0.46
THRB P10828 1/20 0.46
NPY1R P25929 1/20 0.46
SLC2A1 P11166 1/20 0.46
MITF O75030 1/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901866 0.91 ALDH1A1 (0.49) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2901806 0.87 ALDH1A1 (0.51) ALDH1A1MAPTKDM4ENPC1NPSR1
SCHEMBL2908478 0.84 ALDH1A1 (0.52) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2901798 0.77 MAPT (0.50) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2908482 0.75 ALDH1A1 (0.41) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2903263 0.75 ALDH1A1 (0.48) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2904839 0.74 NPSR1 (0.52) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2907733 0.73 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL2905976 0.73 ALDH1A1 (0.54) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL5224886 0.71 PTGS1 (0.37) ALDH1A1MAPTKDM4ENPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885MAPT 1204/4885KDM4E 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.